Article Information
History
- October 10, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Mikaela Moskov1,
- Julia Lindberg Hedlund1,
- Svetlana Popova1,3,
- Maria Lycke2,
- Emma Ivansson1,4,
- Anna Tolf1,3,
- Ulf Gyllensten1,
- Karin Sundfeldt2,
- Karin Stålberg4 and
- Stefan Enroth1,*
- 1Department of Immunology, Genetics, and Pathology, Uppsala University; Biomedical Center, SciLifeLab Uppsala, Uppsala University, SE-75108 Uppsala, Sweden
- 2Department of Obstetrics and Gynaecology, Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University; SE-41685 Gothenburg, Sweden
- 3Department of Clinical Pathology, Akademiska University Hospital; SE-75185 Uppsala, Sweden
- 4Department of Women’s and Children’s Health, Uppsala University; SE-75185 Uppsala, Sweden
- ↵*Corresponding author. Email: Stefan.Enroth{at}igp.uu.se
Posted October 10, 2024.
Deep plasma proteomics identifies and validates an eight-protein biomarker panel that separate benign from malignant tumors in ovarian cancer
